Novan Inc at JMP Securities Life Science Conference Transcript
Ready for our next presentation -- Novan. From the Company today we have Chief Executive Officer, Kelly Martin, and Cole Ikkala, the Director of IR and Business Development.
All right, thank you, Don, and good morning everybody in the room and on the webcast. I will provide a 15- to 20-minute update on Novan. It's a point-in-time update of some recent progress and focus on the near-term. And then we will turn it over to Kelly Martin, our CEO, for Q&A and fireside chat with Don.
The framework in the agenda today is to focus on three things: balance sheet and financial picture; our near-term focus, being the execution of our Phase 3 molluscum program; and finally, some additional business model updates and advancements that we've recently announced and we'll be focused on in the near term.
This presentation will have forward-looking statements. Obviously forward-looking statements are subject to a number of risks and uncertainties. For
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |